During tumor development, Tregs are active in limiting ATP levels and producing adenosine to suppress anti-tumor effector T-cells, as attested by attenuated tumor growth in mice with either CD39-deficient or CD73-deficient Tregs [84,85]. The gene discussed is NT5E; the disease is neoplasm.